Meta Health (SGX:5DX) has amended its acquisition agreement for a 55% stake in Jas Medical Screening Centre, adjusting the terms for performance-based earn-out shares and contingent introducer shares, according to a Thursday filing on the Singapore Exchange.
Under the revised terms, shares will be issued if Jas Medical achieves net profits of at least SG$175,000 in 2025 and 2026, with adjustments linked to changes in Meta's share base.
Independent reviewers will verify the calculations. The company clarified that these amendments do not alter the deal's structure.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。